GSA Capital Partners’s enGene Therapeutics ENGN Stock Holding History

GSA Capital Partners’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65K	Buy	+37,346	New	+$152K	﹤0.01%	1650

Other funds holding ENGN

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Marquette Asset Management Minneapolis, Minnesota $779M AUM 23.4% 1-Year Est. Return

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Fountainhead AM Warren, New Jersey $135M AUM 24.26% 1-Year Est. Return

PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

GSA Capital Partners's ENGN Position: Q2 2026 in Review

GSA Capital Partners opened a new position in enGene Therapeutics (ENGN) in Q2 2026: 37,346 shares worth $65K. The stake represents ﹤0.01% of the portfolio and ranks #1650 among its holdings.

11 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

GSA Capital Partners held 37,346 shares of enGene Therapeutics worth $65K as of Q2 2026.
enGene Therapeutics was a new GSA Capital Partners position in Q2 2026.
enGene Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1650 holding.
11 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.